Stockreport

Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025 [Yahoo! Finance]

Immunovant, Inc.  (IMVT) 
PDF IMVT-1402 development is progressing with potentially registrational studies in GD, myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), di [Read more]